Skip to main content
SpringerLink
Log in

Neurocognition and Treatment Outcomes in Schizophrenia

  • Chapter
  • First Online:
Schizophrenia Treatment Outcomes

Abstract

Neurocognitive deficits affect nearly every aspect of psychosocial and functional outcomes in schizophrenia. In particular, deficits to executive functioning and verbal memory have been found to predict clinical and psychosocial outcomes at every stage of the psychosis spectrum, from clinically high-risk populations to chronic schizophrenia. Baseline cognitive indices provide clinical and prognostic information about daily functioning, community integration, and quality of life and can serve as predictors of health-care-related outcomes as well. While psychotic symptoms of schizophrenia are amenable to pharmacologic interventions, treatment strategies for cognitive symptoms are lacking. From a drug discovery perspective, modulation of glutamatergic and cholinergic pathways is promising, but there are no current FDA-approved medications for the treatment of cognitive symptoms in schizophrenia. As therapeutic options for this disorder continue to grow, including pharmacology, neuromodulation, cognitive remediation, and combinations thereof, these treatments will be made particularly potent if they are applied to biomarker-identified sensitive subgroups of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Vassos E, Sham PC, Cai G, Deng H, Liu X, Sun X, et al. Correlation and familial aggregation of dimensions of psychosis in affected sibling pairs from China. Br J Psychiatry. 2008;193:305–10.

    Article  PubMed  Google Scholar 

  2. McGrath JA, Avramopoulos D, Lasseter VK, Wolyniec PS, Fallin MD, Liang K-Y, et al. Familiality of novel factorial dimensions of schizophrenia. Arch Gen Psychiatry. 2009;66:591–600.

    Article  PubMed  Google Scholar 

  3. Savage RM, Wiener HW, Nimgaonkar V, Devlin B, Calkins ME, Gur RE, et al. Heritability of functioning in families with schizophrenia in relation to neurocognition. Schizophr Res. 2012;139:105–9.

    Article  PubMed  Google Scholar 

  4. Bromley E, Brekke JS. Assessing function and functional outcome in schizophrenia. Curr Top Behav Neurosci. 2010;4:3–21.

    Article  PubMed  Google Scholar 

  5. Harvey PD. Assessing disability in schizophrenia: tools and contributors. J Clin Psychiatry. 2014;75:e27.

    Article  PubMed  Google Scholar 

  6. Heinrichs RW, Statucka M, Goldberg J, McDermid Vaz S. The University of California Performance Skills Assessment (UPSA) in schizophrenia. Schizophr Res. 2006;88:135–41.

    Article  PubMed  Google Scholar 

  7. Mausbach BT, Harvey PD, Goldman SR, Jeste DV, Patterson TL. Development of a brief scale of everyday functioning in persons with serious mental illness. Schizophr Bull. 2007;33:1364–72.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Moore RC, Fazeli PL, Patterson TL, Depp CA, Moore DJ, Granholm E, et al. UPSA-M: feasibility and initial validity of a mobile application of the UCSD performance-based skills assessment. Schizophr Res. 2015;164:187–92.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Velligan DI, Fredrick M, Mintz J, Li X, Rubin M, Dube S, et al. The reliability and validity of the MATRICS functional assessment battery. Schizophr Bull. 2014;40:1047–52.

    Article  PubMed  Google Scholar 

  10. Joseph J, Kremen WS, Glatt SJ, Franz CE, Chandler SD, Liu X, et al. Assessment of Lifespan Functioning Attainment (ALFA) scale: a quantitative interview for self-reported current and functional decline in schizophrenia. J Psychiatr Res. 2015;65:102–7.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Schaefer J, Giangrande E, Weinberger DR, Dickinson D. The global cognitive impairment in schizophrenia: consistent over decades and around the world. Schizophr Res. 2013;150:42–50.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Fatouros-Bergman H, Cervenka S, Flyckt L, Edman G, Farde L. Meta-analysis of cognitive performance in drug-naïve patients with schizophrenia. Schizophr Res. 2014;158:156–62.

    Article  PubMed  Google Scholar 

  13. Evans JD, Heaton RK, Paulsen JS, Palmer BW, Patterson T, Jeste DV. The relationship of neuropsychological abilities to specific domains of functional capacity in older schizophrenia patients. Biol Psychiatry. 2003;53:422–30.

    Article  PubMed  Google Scholar 

  14. Wittorf A, Wiedemann G, Buchkremer G, Klingberg S. Prediction of community outcome in schizophrenia 1 year after discharge from inpatient treatment. Eur Arch Psychiatry Clin Neurosci. 2008;258:48–58.

    Article  PubMed  Google Scholar 

  15. Friedman JI, Harvey PD, Coleman T, Moriarty PJ, Bowie C, Parrella M. Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia: a comparison with Alzheimer’s disease and normal aging. Am J Psychiatry. 2001;158:1441–8.

    Article  PubMed  Google Scholar 

  16. Bodnar M, Malla A, Joober R, Lepage M. Cognitive markers of short-term clinical outcome in first-episode psychosis. Br J Psychiatry. 2008;193:297–304.

    Article  PubMed  Google Scholar 

  17. Chang WC, Ming Hui CL, Yan Wong GH, Wa Chan SK, Ming Lee EH, Hai Chen EY. Symptomatic remission and cognitive impairment in first-episode schizophrenia: a prospective 3-year follow-up study. J Clin Psychiatry. 2013;74:e1046–53.

    Article  PubMed  Google Scholar 

  18. Hofer A, Bodner T, Kaufmann A, Kemmler G, Mattarei U, Pfaffenberger NM, et al. Symptomatic remission and neurocognitive functioning in patients with schizophrenia. Psychol Med. 2011;41:2131–9.

    Article  PubMed  Google Scholar 

  19. Andreou C, Roesch-Ely D, Veckenstedt R, Bohn F, Aghotor J, Köther U, et al. Predictors of early stable symptomatic remission after an exacerbation of schizophrenia: the significance of symptoms, neuropsychological performance and cognitive biases. Psychiatry Res. 2013;210:729–34.

    Article  PubMed  Google Scholar 

  20. Helldin L, Kane JM, Karilampi U, Norlander T, Archer T. Remission and cognitive ability in a cohort of patients with schizophrenia. J Psychiatr Res. 2006;40:738–45.

    Article  PubMed  Google Scholar 

  21. Brissos S, Dias VV, Balanzá-Martinez V, Carita AI, Figueira ML. Symptomatic remission in schizophrenia patients: relationship with social functioning, quality of life, and neurocognitive performance. Schizophr Res. 2011;129:133–6.

    Article  PubMed  Google Scholar 

  22. Niendam TA, Bearden CE, Zinberg J, Johnson JK, O’Brien M, Cannon TD. The course of neurocognition and social functioning in individuals at ultra high risk for psychosis. Schizophr Bull. 2007;33:772–81.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Lin A, Wood SJ, Nelson B, Brewer WJ, Spiliotacopoulos D, Bruxner A, et al. Neurocognitive predictors of functional outcome two to 13 years after identification as ultra-high risk for psychosis. Schizophr Res. 2011;132:1–7.

    Article  PubMed  Google Scholar 

  24. Carrión RE, McLaughlin D, Goldberg TE, Auther AM, Olsen RH, Olvet DM, et al. Prediction of functional outcome in individuals at clinical high risk for psychosis. JAMA Psychiat. 2013;70:1133–42.

    Article  Google Scholar 

  25. Semkovska M, Bédard M-A, Godbout L, Limoge F, Stip E. Assessment of executive dysfunction during activities of daily living in schizophrenia. Schizophr Res. 2004;69:289–300.

    Article  PubMed  Google Scholar 

  26. Fujii DE, Wylie AM. Neurocognition and community outcome in schizophrenia: long-term predictive validity. Schizophr Res. 2003;59:219–23.

    Article  PubMed  Google Scholar 

  27. Seidman LJ, Shapiro DI, Stone WS, Woodberry KA, Ronzio A, Cornblatt BA, et al. Association of neurocognition with transition to psychosis: baseline functioning in the second phase of the north American prodrome longitudinal study. JAMA Psychiat. 2016;73:1239–48.

    Article  Google Scholar 

  28. Seidman LJ, Giuliano AJ, Meyer EC, Addington J, Cadenhead KS, Cannon TD, et al. Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch Gen Psychiatry. 2010;67:578–88.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Addington J, Cornblatt BA, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, et al. At clinical high risk for psychosis: outcome for nonconverters. Am J Psychiatry. 2011;168:800–5.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Sawada K, Kanehara A, Eguchi S, Tada M, Satomura Y, Suga M, et al. Identifying neurocognitive markers for outcome prediction of global functioning in ultra-high-risk for psychosis and first episode psychosis. Psychiatry Clin Neurosci. 2017;71:318–27.

    Article  PubMed  Google Scholar 

  31. Jordan G, Lutgens D, Joober R, Lepage M, Iyer SN, Malla A. The relative contribution of cognition and symptomatic remission to functional outcome following treatment of a first episode of psychosis. J Clin Psychiatry. 2014;75:e566–72.

    Article  PubMed  Google Scholar 

  32. Ventura J, Hellemann GS, Thames AD, Koellner V, Nuechterlein KH. Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. Schizophr Res. 2009;113:189–99.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Thomas ML, Green MF, Hellemann G, Sugar CA, Tarasenko M, Calkins ME, et al. Modeling deficits from early auditory information processing to psychosocial functioning in schizophrenia. JAMA Psychiat. 2017;74:37–46.

    Article  Google Scholar 

  34. Woonings FMJ, Appelo MT, Kluiter H, Slooff CJ, van den Bosch RJ. Learning (potential) and social functioning in schizophrenia. Schizophr Res. 2003;59:287–96.

    Article  PubMed  Google Scholar 

  35. Helldin L, Hjärthag F, Olsson A-K, Harvey PD. Cognitive performance, symptom severity, and survival among patients with schizophrenia spectrum disorder: a rospective 15-year study. Schizophr Res. 2015;169:141–6.

    Article  PubMed  Google Scholar 

  36. Frydecka D, Beszłej JA, Gościmski P, Kiejna A, Misiak B. Profiling cognitive impairment in treatment-resistant schizophrenia patients. Psychiatry Res. 2016;235:133–8.

    Article  PubMed  Google Scholar 

  37. Vinogradov S, Fisher M, Warm H, Holland C, Kirshner MA, Pollock BG. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry. 2009;166:1055–62.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Singh J, Kour K, Jayaram MB. Acetylcholinesterase inhibitors for schizophrenia. Cochrane Database System Rev. 2012;1:CD007967.

    Google Scholar 

  39. Keefe RSE, Meltzer HA, Dgetluck N, Gawryl M, Koenig G, Moebius HJ, et al. Randomized, double-blind, placebo-controlled study of encenicline, an α7 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia. Neuropsychopharmacology. 2015;40:3053–60.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Yang Y, Paspalas CD, Jin LE, Picciotto MR, Arnsten AFT, Wang M. Nicotinic α7 receptors enhance NMDA cognitive circuits in dorsolateral prefrontal cortex. Proc Natl Acad Sci U S A. 2013;110:12078–83.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Thomas EHX, Bozaoglu K, Rossell SL, Gurvich C. The influence of the glutamatergic system on cognition in schizophrenia: a systematic review. Neurosci Biobehav Rev. 2017;77:369–87.

    Article  PubMed  Google Scholar 

  42. Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010;71:138–49.

    Article  PubMed  Google Scholar 

  43. Chengappa KNR, Turkin SR, DeSanti S, Bowie CR, Brar JS, Schlicht PJ, et al. A preliminary, randomized, double-blind, placebo-controlled trial of L-carnosine to improve cognition in schizophrenia. Schizophr Res. 2012;142:145–52.

    Article  PubMed  Google Scholar 

  44. Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 1998;44:1081–9.

    Article  PubMed  Google Scholar 

  45. Kantrowitz JT, Malhotra AK, Cornblatt B, Silipo G, Balla A, Suckow RF, et al. High dose D-serine in the treatment of schizophrenia. Schizophr Res. 2010;121:125–30.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Tsai GE. Ultimate translation: developing therapeutics targeting on N-methyl-d-aspartate receptor. Adv Pharmacol. 2016;76:257–309.

    Article  PubMed  Google Scholar 

  47. de Lucena D, Fernandes BS, Berk M, Dodd S, Medeiros DW, Pedrini M, et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry. 2009;70:1416–23.

    Article  PubMed  Google Scholar 

  48. Veerman SRT, Schulte PFJ, Deijen JB, de Haan L. Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study. Psychol Med. 2017;47:363–75.

    Article  PubMed  Google Scholar 

  49. Light GA, Zhang W, Joshi YB, Bhakta S, Talledo JA, Swerdlow NR. Single-dose memantine improves cortical oscillatory response dynamics in patients with schizophrenia. Neuropsychopharmacology. 2017;42:2633–9.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Lieberman JA, Papadakis K, Csernansky J, Litman R, Volavka J, Jia XD, et al. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology. 2009;34:1322–9.

    Article  PubMed  Google Scholar 

  51. Dickinson D, Tenhula W, Morris S, Brown C, Peer J, Spencer K, et al. A randomized, controlled trial of computer-assisted cognitive remediation for schizophrenia. Am J Psychiatry. 2010;167:170–80.

    Article  PubMed  Google Scholar 

  52. d’Amato T, Bation R, Cochet A, Jalenques I, Galland F, Giraud-Baro E, et al. A randomized, controlled trial of computer-assisted cognitive remediation for schizophrenia. Schizophr Res. 2011;125:284–90.

    Article  PubMed  Google Scholar 

  53. Gomar JJ, Valls E, Radua J, Mareca C, Tristany J, del Olmo F, et al. A multisite, randomized controlled clinical trial of computerized cognitive remediation therapy for schizophrenia. Schizophr Bull. 2015;41:1387–96.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Trapp W, Landgrebe M, Hoesl K, Lautenbacher S, Gallhofer B, Günther W, et al. Cognitive remediation improves cognition and good cognitive performance increases time to relapse–results of a 5 year catamnestic study in schizophrenia patients. BMC Psychiatry. 2013;13:184.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321–30.

    Article  PubMed  Google Scholar 

  56. Bowie CR, Reichenberg A, Patterson TL, Heaton RK, Harvey PD. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am J Psychiatry. 2006;163:418–25.

    Article  PubMed  Google Scholar 

  57. Swerdlow NR, Tarasenko M, Bhakta SG, Talledo J, Alvarez AI, Hughes EL, et al. Amphetamine enhances gains in auditory discrimination training in adult schizophrenia patients. Schizophr Bull. 2017;43:872–80.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA

    Juan Molina & Ming T. Tsuang

Authors
  1. Juan Molina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ming T. Tsuang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ming T. Tsuang .

Editor information

Editors and Affiliations

  1. Lawson Health Research Institute, Western University Lawson Health Research Institute, London, ON, Canada

    Amresh Shrivastava

  2. Lokmanya Tilak Municipal Medical College, De Sousa Foundation, Mumbai, India

    Avinash De Sousa

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Molina, J., Tsuang, M.T. (2020). Neurocognition and Treatment Outcomes in Schizophrenia. In: Shrivastava, A., De Sousa, A. (eds) Schizophrenia Treatment Outcomes. Springer, Cham. https://doi.org/10.1007/978-3-030-19847-3_5

Download citation

Publish with us

Policies and ethics

Search

Navigation